IPP Bureau
Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP
By IPP Bureau - July 14, 2023
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Granules India announces approval for Acetaminophen and Ibuprofen Tablets
By IPP Bureau - July 14, 2023
This product will be launched through Granules Consumer Health (GCH) division
Singapore hosts start-up immersion programme for Indian MBBS doctors
By IPP Bureau - July 11, 2023
The programme was conducted as a part of MPMCx, an exclusive management programme for MBBS doctors by IIM-Ahmedabad in collaboration with DailyRounds
Briefs: Link Pharma Chem and Zydus
By IPP Bureau - July 11, 2023
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
Bausch + Lomb acquires Blink eye drops
By IPP Bureau - July 11, 2023
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData
By IPP Bureau - July 11, 2023
Approval to dramatically change CAR-T therapies landscape
Sumitomo Pharma America launches as new combined organization
By IPP Bureau - July 11, 2023
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Novavax's Nuvaxovid receives full marketing authorization in the EU
By IPP Bureau - July 10, 2023
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Biotech startups are crucial to India’s future economy, says Dr Jitendra Singh
By IPP Bureau - July 10, 2023
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Moderna announces regulatory submissions for its RSV vaccine
By IPP Bureau - July 10, 2023
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Thermo Fisher Scientific to acquire CorEvitas for $912.5 million
By IPP Bureau - July 10, 2023
Advances clinical research capabilities with leading regulatory grade registries platform
Astellas receives FDA priority review for Zolbetuximab biologics license application
By IPP Bureau - July 10, 2023
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
.jpg "L V Prasad Eye Institute and Indian Oil sign MoU to provide care to children with eye cancer")
L V Prasad Eye Institute and Indian Oil sign MoU to provide care to children with eye cancer
By IPP Bureau - July 08, 2023
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
Sirolimus drug coated balloons is an alternative to stents, say Cardiologists
By IPP Bureau - July 08, 2023
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
